

Haematology - HCP



**FABHALTA<sup>®</sup>** ▼  
iptacopan

[Haematology](#)

**FABHALTA<sup>®</sup> ▼ (iptacopan)**

[Prescribing information](#)



**JAKAVI<sup>®</sup>**  
ruxolitinib

Haematology

**JAKAVI<sup>®</sup> (ruxolitinib)**

[Prescribing information](#)



**SCEMBLIX<sup>®</sup>** ▼  
(asciminib) 20 mg, 40 mg tablets

Haematology

**SCEMBLIX®▼ (asciminib)**[Prescribing information](#)

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report), or alternatively email [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com) or call 01276 698370.

---

**Source URL:** <https://www.pro.novartis.com/uk-en/medicines/haematology>